Pregnancy Clinical Trial
Official title:
Are IQs Low in Offspring of Euthyroid Women With Low T4?
This study is designed to test the hypothesis that the level of the thyroid hormone thyroxine (specifically, free thyroxine, FT4) circulating in the blood of pregnant women is the key thyroid-related factor to influence early fetal brain development. The investigators will recruit 5000 pregnant women with clinically normal thyroid function (normal thyroid stimulating hormone levels) in the second trimester. After the baby has been born, the investigators will measure FT4 in the second trimester maternal blood sample to identify 100 cases (very low FT4 levels) and 100 matched controls (normal FT4 levels). The children of cases and controls will undergo neurodevelopmental testing at 2 years of age to determine whether IQ differs according to maternal FT4 levels during pregnancy. The potential impact of the study is that if such an effect is found, it might be possible to avoid these adverse developmental consequences in children by designing and testing strategies to identify and treat high risk women.
Summary:
The purpose of the proposed study is to test the hypothesis that the key thyroid-related
factor in early fetal brain development is T4 derived from the maternal circulation.
According to this hypothesis, low circulating maternal levels of free T4 may adversely
influence fetal brain development, even when the mother is clinically euthyroid (i.e. has
normal TSH levels).
Specific Aims:
The proposed project aims to determine whether free T4 levels at or below the 3rd centile in
euthyroid women during early pregnancy are associated with reduced neuropsychological
development in their offspring. We will recruit a cohort of 5,000 pregnant women whose serum
samples have been submitted for routine prenatal screening for Down syndrome and neural tube
defects in the early second trimester of pregnancy. After the women provide consent,
thyroid-stimulating hormone (TSH) measurements will be performed. The women defined as
euthyroid by TSH measurement will comprise the study group. Free T4 measurements will be
performed on their stored sera after delivery. Then, a nested case-control study design will
be used. Inclusion criteria will include: liveborn, singleton infant delivered in Maine at
36 weeks or later, weighing at least 2,500 grams, and with no reported congenital anomalies.
Multiple gestations will be excluded. Eligible women with free T4 measurements below the 3rd
percentile (cases) will each be matched with a woman/infant pair with normal free T4
measurements (controls). Overall, 100 offspring in each category will undergo
neurodevelopmental testing at age 2 years, using a test battery that will focus on language
development and attainment of milestones and motor development. The study will have an 80%
power to detect a 6 point difference in full scale IQ.
Study Timeline:
Phase 1. Preparation for Recruitment (months 1-4):
Validate reference ranges for TSH and Free T4 Assays; Implement clinical reporting and
management system for TSH measurements; design and implement a Data Management System;
develop Provider and patient materials; visit offices to introduce the project; develop
informed consent.
Phase 2. Active Recruitment (months 4-24):
Recruit 5,000 pregnant women, classified as euthyroid based on second trimester TSH
measurements; measure free T4 measured in stored serum aliquots after the pregnancies have
delivered.
Phase 3. Identification of Study Subjects (months 18-36):
Identify 100 cases (euthyroid women fulfilling all inclusion criteria and with free T4
measurements at or below the 3rd centile) and 100 matched controls (normal free T4) among
the 5,000 euthyroid recruits.
Phase 4. Locate/Recruit Cases and Controls (months 20-38):
Locate and re-recruit the women/infant pairs identified in phase 3; obtain newborn
hypothyroidism screening results.
Phase 5. Neurodevelopmental Testing (months 36-58):
Perform neurodevelopmental testing and measure other thyroid analytes (total T4, T3 and
thyroid antibodies) in the cases and controls.
Phase 6. Data Analysis (months 59-60):
Compare demographic data, along with pregnancy- and delivery-related information, between
case and control mother/child pairs to verify matching and to compare non-matched variables
between the two groups. Include covariates that differ significantly between cases and
controls (and that might be related to neurodevelopment) in a more refined model to
determine whether the unadjusted findings are robust.
Significance:
The knowledge gained from this study will expand our understanding of the role that thyroid
hormone plays in normal pregnancy. If the hypothesis under study in this proposal proves to
be correct, it will define a broader group of pregnancies in which fetal brain development
might be suboptimal. The primary benefit to documenting such a problem would be the
opportunity to develop strategies for identifying and treating high risk women to avoid the
adverse consequences in their children.
;
Observational Model: Case Control, Time Perspective: Cross-Sectional
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03442582 -
Afluria Pregnancy Registry
|
||
Terminated |
NCT02161861 -
Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study
|
N/A | |
Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
Enrolling by invitation |
NCT05415371 -
Persistent Poverty Counties Pregnant Women With Medicaid
|
N/A | |
Completed |
NCT04548102 -
Effects of Fetal Movement Counting on Maternal and Fetal Outcome Among High Risk Pregnant Woman
|
N/A | |
Completed |
NCT03218956 -
Protein Requirement During Lactation
|
N/A | |
Completed |
NCT02191605 -
Computer-delivered Screening & Brief Intervention for Marijuana Use in Pregnancy
|
N/A | |
Completed |
NCT02223637 -
Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry
|
||
Recruiting |
NCT06049953 -
Maternal And Infant Antipsychotic Study
|
||
Completed |
NCT02577536 -
PregSource: Crowdsourcing to Understand Pregnancy
|
||
Not yet recruiting |
NCT06336434 -
CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT04786587 -
Alcohol Self-reporting During Pregnancy. AUTOQUEST Study.
|
||
Not yet recruiting |
NCT05412238 -
Formulation and Evaluation of the Efficacy of Macro- and Micronutrient Sachets on Pregnant Mothers and Children Aged 6-60 Months
|
N/A | |
Not yet recruiting |
NCT05028387 -
Telemedicine Medical Abortion Service Using the "No-test" Protocol in Ukraine and Uzbekistan.
|
||
Completed |
NCT02783170 -
Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women
|
Phase 4 | |
Completed |
NCT02683005 -
Study of Hepatitis C Treatment During Pregnancy
|
Phase 1 | |
Recruiting |
NCT02507180 -
Safely Ruling Out Deep Vein Thrombosis in Pregnancy With the LEFt Clinical Decision Rule and D-Dimer
|
||
Recruiting |
NCT02619188 -
Nutritional Markers in Normal and Hyperemesis Pregnancies
|
N/A | |
Recruiting |
NCT02564250 -
Maternal Metabolism and Pregnancy Outcomes in Obese Pregnant Women
|
N/A | |
Terminated |
NCT02537145 -
PregnanT Moms Measure - Do-It-Yourself Health Monitoring and Simulation of Health in Pregnant Women
|